Litcius/Paper detail

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Shengli Xia, Yuntao Zhang, Yanxia Wang, Hui Wang, Yunkai Yang, George F. Gao, Wenjie Tan, Guizhen Wu, Miao Xu, Zhiyong Lou, Weijin Huang, Wenbo Xu, Baoying Huang, Huijuan Wang, Wei Wang, Wei Zhang, Na Li, Zhiqiang Xie, Ling Ding, Wangyang You, Yuxiu Zhao, Xuqin Yang, Yang Liu, Qian Wang, Lili Huang, Yongli Yang, Guangxue Xu, Bojian Luo, Bojian Luo, Peipei Liu, Wanshen Guo, Xiaoming Yang, Xiaoming Yang, Xiaoming Yang

2020The Lancet Infectious Diseases1,210 citationsDOIOpen Access PDF

Topics & Concepts

MedicinePlaceboImmunogenicityTolerabilityClinical trialRandomized controlled trialInternal medicineAdverse effectImmunologyAntibodyPathologyAlternative medicineSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studiesvaccines and immunoinformatics approaches
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial | Litcius